ClinicalTrials.gg
Active, not recruitingNCT06293365Updated Oct 14, 2026

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

A Phase 2 interventional study of VAY736 1ml PFS and VAY736 2 ml PFS in Sjögrens Disease, Systemic Lupus Erythematosus and Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 37 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Basic science

Updated Oct 14, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Lupus Erythematosus, Systemic by Novartis — 2 open to participants now, 8 under way, 4 of them phase 3. Lupus Erythematosus, Systemic · Novartis.

Enrollment
7th of 14
155 · median 131
Started
2024
with 4 others
Phase 2
4 of 14
none open now
Registered
10th of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Novartis, this one is the 7th largest by enrollment, is one of 5 that started in 2024, is one of 4 in phase 2, and was the 10th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE).

A second cohort will be included with the objective of demonstrating the comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS) and 2 x 1 mL PFS.

Read the detailed description

The study consists of the following periods:

Screening period (up to 4 weeks):

Following the signing of the informed consent, participants will be assessed for eligibility during this period of up to 4 weeks.

Treatment Period 1 + Treatment Period 2, (Week 0 to Week 24):

After completion of the screening period, eligible participants will be randomized at the Baseline visit (Week 0) to one of the 2 treatment sequences (treatment switch at Week 12) in a ratio of 1:1 described below:

  • Cohort 1:

    • Sequence 1: ianalumab 300 mg s.c. (2 x 1 mL PFS) monthly + SoC in Treatment Period 1 and ianalumab 300 mg s.c. (1 x 2 mL AI) monthly + SoC in Treatment Period 2
    • Sequence 2: ianalumab 300 mg s.c. (1 x 2 mL AI) monthly + SoC in Treatment Period 1 and ianalumab 300 mg s.c. (2 x 1 mL PFS) monthly + SoC in Treatment Period 2
  • Cohort 2:

    • Sequence 1: ianalumab 300 mg s.c. (2 x 1 mL PFS) monthly + SoC in Treatment Period 1 and ianalumab 300 mg s.c. (1 x 2 mL PFS) monthly + SoC in Treatment Period 2
    • Sequence 2: ianalumab 300 mg s.c. (1 x 2 mL PFS) monthly + SoC in Treatment Period 1 and ianalumab 300 mg s.c. (2 x 1 mL PFS) monthly + SoC in Treatment Period 2 In addition, within each sequence, participants will be further randomized to one of the predetermined injection sites with equal allocation, resulting in a total randomization combination of four (2 sequences x 2 injection sites) for Cohort 1 and six (2 sequences x 3 injection sites) for Cohort 2, respectively.

Extended Treatment period (Week 24 to Week 72): After completion of Week 24 assessment, all participants (who did not discontinue during treatment period) will have the option to enter the extended treatment period to receive ianalumab 300 mg s.c. (Cohort 1: 2 mL AI; Cohort 2: 2 x 1 mL PFS) monthly up to Week 68. The end of treatment (EOT) visit will be performed 4 weeks after the last study treatment administration, i.e., at Week 72.

Mandatory Post-Treatment safety follow-up period (from Week 72 to Week 88): Participants who completed the last study treatment or prematurely discontinued from study treatment will enter the post-treatment safety follow-up period.

Conditional Post-Treatment safety follow-up period (from Week 88 to Week 176) Post-treatment follow-up will be performed until B-cell recovery or up to 2 years. B-cell recovery is defined when CD19+ B-cell counts return to >= 50 cells/μL or >= 80% of baseline value, whichever occurs earlier.

03

Conditions studied

  • Sjögrens Disease
  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis

Keywords

  • Sjögrens Disease (SjD)
  • Systemic lupus erythematosus (SLE)
  • Rheumatoid Arthritis (RA)
  • Pharmacokinetic (PK) comparability
  • 2 mL auto-injector (AI)
  • 1 mL pre-filled syringe (PFS)
  • 2 mL pre-filled syringe (PFS)
  • VAY736
  • ianalumab
  • B cell depletion
  • Area under the curve (AUC)
  • Cmax
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Signed must be obtained before any assessment is performed.
  • Male and female patients aged 18 years to 70 years (inclusive).
  • Body weight at least 35 kg and not more than 150 kg and must have a (BMI) within the range of 18 - 35 kg/m2. BMI = Body weight (kg) / [Height (m)]2 at screening.
  • Diagnosed with RA, SjD and/or SLE as determined by the investigator.
  • Have active disease (RA, SjD or SLE) that may benefit from B-cell depletion therapy, as determined by the investigator.
  • Participants currently receiving protocol-allowed SoC should be on stable doses of SoC medications for 4 weeks prior to first dosing of study treatment.
  • Ability to communicate well with the investigator, understand and agree to comply with the requirements of the study.

Key Exclusion criteria:

  • Use of prohibited therapies.
  • Active viral, bacterial or other infections requiring systemic treatment at the time of screening or baseline or history of recurrent infection.
  • Plans for administration of during the study period.
  • Uncontrolled co-existing serious disease.
  • Pregnant or nursing (lactating) women.
  • Women of (WOCBP), defined as all women physiologically capable of becoming pregnant, refusing or unable to use highly effective methods of while on study treatment and for 6 months after stopping of study drug.
  • US (and other countries, if locally required): sexually active males unless using barrier protection during intercourse with women of child-bearing potential while taking study treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Cohort 1: Sequence 1 + Thigh

    Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh (1 X 2 mL) AI in TP2 in Thigh (1 x 2 mL) AI in ETP in Thigh/ Abdomen

    Biological: VAY736 1ml PFS · Biological: VAY736 2ml AI

  • Experimental
    Cohort 1: Sequence 1 + Abdomen

    Patients randomized to receive injection 1. X 2 mL) AI in TP1 in Abdomen 2. x 1 mL) PFS in TP2 in Abdomen (1 x 2 mL) AI in ETP in Thigh/ Abdomen

    Biological: VAY736 1ml PFS · Biological: VAY736 2ml AI

  • Experimental
    Cohort 1: Sequence 2 + Thigh

    Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh (1 X 2 mL) AI in TP2 in Thigh (1 x 2 mL) AI in ETP in Thigh/ Abdomen

    Biological: VAY736 1ml PFS · Biological: VAY736 2ml AI

  • Experimental
    Cohort 1: Sequence 2 + Abdomen

    Patients randomized to receive injection 1. X 2 mL) AI in TP1 in Abdomen 2. x 1 mL) PFS in TP2 in Abdomen (1 x 2 mL) AI in ETP in Thigh/ Abdomen

    Biological: VAY736 1ml PFS · Biological: VAY736 2ml AI

  • Experimental
    Cohort 2: Sequence 1 + Thigh

    Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Thigh 1. X 2 mL) PFS in TP2 in Thigh 2. x 1 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm

    Biological: VAY736 1ml PFS · Biological: VAY736 2 ml PFS

  • Experimental
    Cohort 2: Sequence 1 + Abdomen

    Patients randomized to receive injection 1. X 2 mL) PFS in TP1 in Abdomen 2. x 1 mL) PFS in TP2 in Abdomen (2 x 1 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm

    Biological: VAY736 1ml PFS · Biological: VAY736 2 ml PFS

  • Experimental
    Cohort 2: Sequence 1 + Upper Arm

    Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Upper Arm 1. X 2 mL) PFS in TP2 in Upper Arm 2. x 1 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm

    Biological: VAY736 1ml PFS · Biological: VAY736 2 ml PFS

  • Experimental
    Cohort 2: Sequence 2 + Thigh

    Patients randomized to receive injection 1. X 2 mL) PFS in TP1 in Thigh 2. x 1 mL) PFS in TP2 in Thigh (2 x 1 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm

    Biological: VAY736 1ml PFS · Biological: VAY736 2 ml PFS

  • Experimental
    Cohort 2: Sequence 2 + Abdomen

    Patients randomized to receive injection (2 x 1 mL) PFS in TP1 in Abdomen 1. X 2 mL) PFS in TP2 in Abdomen 2. x 1 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm

    Biological: VAY736 1ml PFS · Biological: VAY736 2 ml PFS

  • Experimental
    Cohort 2: Sequence 2 + Upper Arm

    Patients randomized to receive injection 1. X 2 mL) PFS in TP1 in Upper Arm 2. x 1 mL) PFS in TP2 in Upper Arm (2 x 1 mL) PFS in ETP in Thigh/ Abdomen/ Upper Arm

    Biological: VAY736 1ml PFS · Biological: VAY736 2 ml PFS

Interventions

  • BiologicalVAY736 1ml PFS

    Solution for injection.

    Also known as: Ianalumab

  • BiologicalVAY736 2 ml PFS

    Solution for injection

    Also known as: Ianalumab

  • BiologicalVAY736 2ml AI

    Solution for injection.

    Also known as: Ianalumab

06

What researchers measure

Primary outcomes

  1. Cohort 1: Area under the curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) for ianalumab

    To demonstrate the pharmacokinetics (PK) comparability of ianalumab 300 mg s.c. at steady state between the 1 x 2 mL AI and 2 x 1 mL PFS

    Time frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).

  2. Cohort 1: Maximum (peak) observed serum drug concentration after dose administration (Cmax) for ianalumab

    To demonstrate the pharmacokinetics (PK) comparability of ianalumab 300 mg s.c. at steady state between the 1 x 2 mL AI and 2 x 1 mL PFS

    Time frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).

  3. Cohort 2: Area under the curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) for ianalumab

    To demonstrate the pharmacokinetics (PK) comparability of ianalumab 300 mg s.c. at steady state between the 1 x 2 mL PFS and 2 x 1 mL PFS.

    Time frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).

  4. Cohort 2: Maximum (peak) observed serum drug concentration after dose administration (Cmax) for ianalumab

    To demonstrate the pharmacokinetics (PK) comparability of ianalumab 300 mg s.c. at steady state between the 1 x 2 mL PFS and 2 x 1 mL PFS.

    Time frame: Over a dosing interval after 3rd (between Week 8 and 12) and 6th dose (between Week 20 and 24).

Secondary outcomes

  1. Cohort 1: Time to reach maximum (peak) serum drug concentration following dose administration (Tmax) for ianalumab

    To evaluate the pharmacokinetics of ianalumab 300 mg s.c. at steady state under the 1 x 2 mL AI and 2 x 1 mL PFS

    Time frame: After the 3rd and 6th dose

  2. Cohort 2: Time to reach maximum (peak) serum drug concentration following dose administration (Tmax) for ianalumab

    To evaluate the pharmacokinetics of ianalumab 300 mg s.c. at steady state under the 1 x 2 mL PFS and 2 x 1 mL PFS

    Time frame: After the 3rd and 6th dose

  3. Cohort 1: Concentration at the end of a dosing interval (Ctrough) for ianalumab

    To evaluate the pharmacokinetics of ianalumab 300 mg s.c. at steady state under the 1 x 2 mL AI and 2 x 1 mL PFS

    Time frame: At the end of dosing interval

  4. Cohort 2: Concentration at the end of a dosing interval (Ctrough) for ianalumab

    To evaluate the pharmacokinetics of ianalumab 300 mg s.c. at steady state under the 1 x 2 mL PFS and 2 x 1 mL PFS

    Time frame: At the end of dosing interval

  5. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To evaluate the safety and tolerability of ianalumab administered 300 mg s.c. monthly.

    Time frame: From date of randomization until 30 days safety follow-up, assessed up to approximately 56 months

  6. Anti-ianalumab antibodies (ADA)

    To assess the immunogenicity of ianalumab administered 300 mg s.c. monthly

    Time frame: From date of randomization until 30 days safety follow-up, assessed up to approximately 56 months

  7. Incidence of ADA positive participants

    To assess the immunogenicity of ianalumab administered 300 mg s.c. monthly

    Time frame: From date of randomization until 30 days safety follow-up, assessed up to approximately 56 months

07

Study locations

37 sites
  • Pinnacle Research Group Llc
    Anniston, Alabama 36207, United States
  • Providence Medical Foundation
    Fullerton, California 92835, United States
  • Advanced Medical Research
    La Palma, California 90623, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Parris and Associates Rheumatology
    Lawrenceville, Georgia 30044, United States
  • Indiana Univ School of Dentistry
    Indianapolis, Indiana 46202, United States
  • Ochsner Health System
    Baton Rouge, Louisiana 70809, United States
  • Ahmed Arif Medical Research Center
    Grand Blanc, Michigan 48439, United States
  • Paramount Med Rsrch and Consult LLC
    Middleburg Heights, Ohio 44130, United States
  • RAO Research LLC
    Oklahoma City, Oklahoma 73116, United States
  • Altoona Center for Clin Res
    Duncansville, Pennsylvania 16635, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Shelby Research LLC
    Memphis, Tennessee 38119, United States
  • Novel Research LLC
    Bellaire, Texas 77401, United States
  • Southwest Rheum Rsrch LLC
    Mesquite, Texas 75150, United States
  • Uni of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382, United States
  • Novartis Investigative Site
    Quilmes, Buenos Aires 1878, Argentina
  • Novartis Investigative Site
    San Miguel Tucuman, Tucumán Province T4000DPK, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1055AAF, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1437FFC, Argentina
  • Novartis Investigative Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5T 2S8, Canada
  • Novartis Investigative Site
    Rimouski, Quebec G5L 5T1, Canada
  • Novartis Investigative Site
    Trois-Rivières, Quebec G9A 3Y2, Canada
  • Novartis Investigative Site
    Brno, 638 00, Czechia
  • Novartis Investigative Site
    Prague, 128 00, Czechia
  • Novartis Investigative Site
    Uherské Hradiště, 686 01, Czechia
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, 1027, Hungary
  • Novartis Investigative Site
    Budapest, 1134, Hungary
  • Novartis Investigative Site
    Salerno, SA 84131, Italy
  • Novartis Investigative Site
    Krakow, 30-002, Poland
  • Novartis Investigative Site
    Lublin, 20-607, Poland
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    A Coruña, 15006, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Feb 2026, 19 months.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 19 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 5, 2024
StartActual
Jul 2, 2024
Primary completionActual
Feb 17, 2026
CompletionEst.
Jan 16, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Advanced Rheumatology of Houston · The Woodlands, United States
Show 1 removed
  • Advanced Rheumatology of Houston · Spring, United States
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    1 site added, 1 site removed
    Show site
    • Advanced Rheumatology of Houston · The Woodlands, United States
    Show 1 removed
    • Advanced Rheumatology of Houston · Spring, United States
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06293365
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
Jul 2, 2024
Primary completion
Feb 17, 2026
Completion
Jan 16, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion